Biomea Fusion, Inc. Lawsuit Submission Form

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Owned

Purchase Date

Estimated Loss

Stock Fraud Law Center does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

Biomea issued a press release on June 6, 2024, announcing that it “has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.”

Following this news, shares of Biomea fell over 59% in after hours trading on the same day.

Active Cases

Ticker Symbol	Company Name	Join Deadline	Join
WOLF	Wolfspeed, Inc.	January 17, 2025	Join
SUI	Sun Communities, Inc.	February 10, 2025	Join
SAVA	Cassava Sciences, Inc.	February 10, 2025	Join
APLT	Applied Therapeutics, Inc.	February 18, 2025	Join
BIOA	BioAge Labs, Inc.	March 10, 2025	Join
PCRX	Pacira BioSciences, Inc.	March 14, 2025	Join

Biomea Fusion, Inc.

BMEA

Biomea Fusion, Inc. Form

Active Cases